– CANADA, Toronto – FSD Pharma Inc. (Nasdaq: HUGE | CSE: HUGE | FRA: 0K9) today announced the appointment of Adnan Bashir to its Board as an Independent Director, succeeding Frank Lavelle who resigned shortly after his appointment.
“Adnan’s wealth of experience will add significant value to our Board,” said co-founder and co-chairman, Anthony Durkacz. “We look forward to working with him as we restore FSD.”
The Board is now comprised of:
- Anthony Durkacz,
- Zeeshan Saeed,
- Nitin Kaushal,
- Larry Latowsky,
- Fernando Cugliari,
- Donal Carroll
- Adnan Bashir.
About Adnan Bashir
Adnan Bashir has over 14 years of experience in strategic management and operations. In the last decade, Mr. Bashir was General Manager for Al Batha Group, a diversified business conglomerate based in Dubai, UAE. Mr. Bashir was responsible for overseeing the management and operations of 4 companies within the group and was instrumental in acquiring and developing new businesses and partners from Europe, the US, and China. Mr. Bashir also has extensive experience in executing turnaround strategies, transforming weak businesses into sustainable and profitable ones, and implementing new technologies.
Mr. Bashir holds a Bachelor of Science Degree in Mechanical Engineering from the University of Engineering and Technology Lahore and has completed extensive executive education, including in strategic management, audit, sales management, and technical management.
About FSD Pharma
FSD Pharma Inc., a wholly-owned subsidiary, is a specialty biotech pharmaceutical R&D company focused on developing multiple applications of its lead compound, ultramicro PEA by down-regulating the cytokines to effectuate an anti-inflammatory response.
For more information: https://fsdpharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
